Novo Nordisk Cuts Prices of Ozempic, Wegovy, and Rybelsus

Novo Nordisk announced significant price reductions for its popular GLP-1 medications – Ozempic, Rybelsus, and Wegovy – in an effort to expand access to these drugs. The price cuts, effective January 1, 2027, will bring the monthly list price for each medication down to $675 , , .

Why the Price Cuts?

Currently, these medications each have list prices exceeding $1,000 per month, with Wegovy being the most expensive at $1,349 . Novo Nordisk states the reductions are intended to benefit patients with insurance plans that base coverage on list prices, particularly those with high-deductible plans or coinsurance . The move also comes amid increasing competition from Eli Lilly, whose obesity drug Zepbound is gaining market share .

Who Will Observe Savings?

The price reductions will primarily impact individuals with insurance plans where out-of-pocket costs are tied to the list price of the medication. Those who pay cash for their prescriptions or have already benefited from previous price drops – Novo Nordisk previously reduced the price of Wegovy and some Ozempic dosages to $349 a month for direct purchases – may not see additional savings .

Impact of Competition and Clinical Trial Results

Novo Nordisk’s decision follows the release of late-stage study results showing that its next-generation obesity drug, CagriSema, did not result in as much weight loss as Eli Lilly’s Zepbound . The announcement of these results led to a 16% drop in Novo Nordisk’s shares on Monday, February 23, 2026 .

Looking Ahead

Novo Nordisk anticipates that these price cuts will improve access and uptake of its GLP-1 medications within the commercial insurance market, though specific expectations have not been released . The company aims to remain competitive in the rapidly evolving market for obesity and diabetes treatments.